Skip to content

Trial Summary

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Acronym:

EVX MELANOMA

ACTRN/NCT /ethics:

NCT04455503

Scientific title:

A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence

Sponsor / Cooperative group:

Evaxion Biotech A/S

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-07-13
Anticipated End Date2024-03-31

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Amitesh Roy
Recruitment StatusRecruiting